Back to Newsroom

Motif Bio Update on NDA Submission for Iclaprim

NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (MTFB.L) (MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today provided an update on the status and timeline for submission of its New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for its targeted, Gram-positive investigational antibiotic, iclaprim, for the treatment of acute bacterial skin and skin structure infections (ABSSSI).